miR-192 and SLC39A6 might be useful indicators for HCC patient outcomes, and the miR-192/SLC39A6/SNAIL pathway might be a promising therapeutic target for HCC treatment. This evidence concerns the gene SLC39A6 and hepatocellular carcinoma.